Figure 2:
Kaplan‒Meier curves of survival probability by eGFR categories. Survival probability for primary (A and B for total stroke) and secondary outcomes (C and D for ischemic stroke; E and F for hemorrhagic stroke) according to the categories of eGFRcys and eGFRcr. The median follow-up period for total stroke was 10.11 (IQR 9.39–10.81) years, that for ischemic stroke was 10.11 (IQR 9.40–10.81) years and for hemorrhagic stroke was 10.11 (IQR 9.40–10.82) years. In the participants who experienced stroke, the median follow-up periods were 5.01 (IQR 2.98–6.62), 5.04 (IQR 3.01–6.66) and 4.92 (IQR 2.90–6.55) years for total stroke, ischemic stroke and hemorrhagic stroke, respectively. The median follow-up period for participants who did not develop stroke was 10.17 (IQR 9.48–10.84) years. eGFRcr, estimated glomerular filtration rate based on serum creatinine calculated with the Chronic Kidney Disease Epidemiology Collaboration equation; eGFRcys, estimated glomerular filtration rate based on serum cystatin C calculated with the Chronic Kidney Disease Epidemiology Collaboration equation; IQR, interquartile range.